BioSpace News Archive

Cannabis testing entails detecting traces of the illicit drug in people. Also, referred to as grass, marijuana, dope, pot, weed, joints, hash, joints, and so on, it is often used in sports or medicine to reduce pain, bring about muscle relaxation, and reduce stress.

Grifols, a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, announced it’s collaborating with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR® Center, where AMBAR® procedure for Alzheimer’s disease will be applied to obtain data from clinical practice.

The International Myeloma Foundation said that research published this week in Blood Cancer Journal could lead to a paradigm shift in myeloma therapy towards screening for the precursor for the disease and treating early.

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, announced that it will present and participate in one-on-one investor meetings at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.

Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by Multiple Clinical Sites in Japan

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it received a communication from the Division of Neurology Products 1 (“Division”) of the U.S. Food and Drug Administration (“FDA”)

Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors.

Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management will participate in Cowen’s 2nd Annual Virtual Oncology Innovation Summit. MacroGenics’ management will participate in a fireside chat with the analyst on Thursday, May 20, 2021, at 9:20 am ET.

TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today launched the company’s second post-market study, BRAVO II, to evaluate the clinical performance of OviTex® Reinforced Tissue Matrices in the robotic repair of ventral hernias.